Physician profile
Victor E Seikaly
NPI 1235158320
$6,918.82
in general payments reported to CMS, 2019-2025
36 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $778 · 2021: $1,621 · 2022: $1,259 · 2023: $925 · 2024: $937 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $838.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $717.81 | 2020-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Pfizer INC. | $656.89 | 2019-2025 | |
| Lilly USA, LLC | $574.10 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $567.83 | 2019-2025 | Andexxa, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.85 | 2019-2025 | Ofev, Jascayd |
| Janssen Pharmaceuticals, INC | $398.64 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $323.67 | 2019-2024 | Dificid |
| Abbvie INC. | $310.10 | 2021-2025 | Teflaro |
| Daiichi Sankyo INC. | $303.53 | 2020-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $241.03 | 2019-2022 | |
| Gilead Sciences, INC. | $192.83 | 2020-2024 | |
| Boston Scientific Corporation | $175.71 | 2019-2025 | Watchman Flx |
| Biomerieux INC | $111.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.74 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $100.09 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $99.04 | 2019-2023 | Camzyos |
| Astellas Pharma US INC | $94.03 | 2019-2024 | Veozah |
| Philips North America LLC | $67.92 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.92 | 2022-2025 | Xifaxan |
| Baxter Healthcare | $48.15 | 2022 | |
| Currax Pharmaceuticals LLC | $47.60 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $40.81 | 2019-2021 | |
| Advanced Respiratory, INC | $40.44 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $37.58 | 2021 | |
| Exact Sciences Corporation | $36.24 | 2023-2025 | Cologuard Collection Kit |
| Radius Health, INC. | $31.34 | 2023 | |
| Shionogi INC | $25.85 | 2025 | Fetroja |
| Abbott Laboratories | $24.19 | 2023 | Cardiomems |
| Otsuka America Pharmaceutical, INC. | $23.99 | 2019 | |
| Amarin Pharma, INC. | $21.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.02 | 2022 | |
| Mylan Specialty L.P. | $19.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.38 | 2023 | Livalo |
| Sanofi-Aventis U.S. LLC | $15.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Seikaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.